Surveillance of Human Papilloma Virus in the United States to Evaluate Vaccine Impact

Authors

  • Andrew Wilson Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT, United States
  • Ryan Welch ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States
  • Rosemary She University of Southern California Keck Medical Center, Los Angeles, CA, United States

DOI:

https://doi.org/10.5210/ojphi.v6i1.5172

Abstract

Background: Human papillomavirus (HPV) is a vaccine-preventable virus that can cause cervical cancer.  Widespread positivity rates in target groups before and since the introduction of the vaccine in 2006 would provide insight into the uptake of the vaccine. Data: Archived patient records were queried and formatted to allow analysis and determination of positivity rates. Results/Conclusions: Positivity rate estimates show a decrease in positivity for younger age groups. From 2004 to 2013, high-risk rates dropped 20% in women 14-24 years. After the vaccine introduction, HPV positivity has declined at a rate consistent with widespread inoculation, especially in younger women.

Author Biography

Andrew Wilson, Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT, United States

Andrew Wilson is a Public Health PhD Candidate in the University of Utah School of Medicine. His academic work focuses on HPV vaccination and the impact of vaccination on HPV rates.

Downloads

Published

2014-03-09

How to Cite

Wilson, A., Welch, R., & She, R. (2014). Surveillance of Human Papilloma Virus in the United States to Evaluate Vaccine Impact. Online Journal of Public Health Informatics, 6(1). https://doi.org/10.5210/ojphi.v6i1.5172

Issue

Section

Oral Presentations